Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Spätfolgen nach Immuntherapie: Immunvermittelte Nebenwirkungen von Checkpointinhibitoren (2021) Duong SL, Zierold S, Kramer R, Reincke M, Kerl-French K, Boehmerle W, Pavel ME, et al. Journal article, Review article Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? (2021) Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, et al. Journal article, Review article Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ (2021) Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, et al. Journal article Immunoprofiling in neuroendocrine neoplasms unveil immunosuppressive microenvironment (2020) Busse A, Mochmann LH, Spenke C, Arsenic R, Briest F, Jöhrens K, Lammert H, et al. Journal article Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results (2020) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution SERIO - Side Effect Registry Immuno-Oncology Side Effect Registry for rare, severe and complex Side Effects of Immunotherapy (2020) Kramer R, Mentzer D, Erdmann M, Knauss S, Broeckelmann PJ, Hassel JC, Ugurel S, et al. Conference contribution Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? (2020) Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, et al. Journal article Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms (2020) Merola E, Dal Buono A, Denecke T, Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME Journal article Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (United States) and the prospective diabetes follow-up (Germany/Austria) registries (2020) Shah VN, Grimsmann JM, Foster NC, Dost A, Miller KM, Pavel ME, Weinstock RS, et al. Journal article CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen (2020) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Xuan-Mai Truong Thanh , et al. Conference contribution